01 / DESIGN
What was studied?
SURMOUNT-1 assigned 2,539 adults to tirzepatide study groups or placebo for 72 weeks. Participants had obesity, or overweight with a weight-related complication, and did not have diabetes.
02 / FINDINGS
What did the researchers report?
Average weight reduction was greater in the tirzepatide groups than with placebo. Gastrointestinal events were the most common adverse effects; some participants stopped treatment because of adverse events.
03 / LIMITS
How should it be interpreted?
The findings apply to the studied pharmaceutical regimens and eligibility criteria. They do not establish universal outcomes, indefinite durability or equivalence between a clinical study product and catalog materials.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.